Wellgistics 2025 Q3 Earnings Sharp Net Loss Widens 1738% Despite Revenue Decline

Wellgistics (WGRX) reported a 46.9% year-over-year revenue drop to $3.01 million in Q3 2025, alongside a net loss of $34.32 million—a 1738.1% increase from 2024 Q3. The results fell far below expectations, with no guidance adjustments provided. Management flagged ongoing operational challenges and raised concerns about the company’s ability to continue as a going concern, underscoring the severity of its financial distress.

Revenue

Wellgistics’ Q3 2025 revenue contraction was driven by a sharp decline in sales volume across all segments. Distribution services, its largest revenue stream, contributed $2.64 million, while pharmacy retail sales and third-party logistics services added $172,100 and $203,014, respectively. The combined segment performance reflects a significant reduction in market demand and operational efficiency.

Earnings/Net Income

The company’s net loss widened to $34.32 million in Q3 2025, or $0.46 per share, compared to a $1.87 million loss ($0.04 per share) in the prior-year period. This represents a 1050% increase in per-share losses and a 1738.1% surge in total losses. The EPS and net loss figures indicate a significant deterioration in profitability, with the company posting a substantial loss per share and an unprecedented net loss.

Post-Earnings Price Action Review

The strategy of purchasing Wellgistics shares on the date of its earnings announcement and holding for 30 days has historically underperformed. The stock price declined 0.56% on the release date and dropped further by 3.22% by the end of the 30-day holding period. Over extended horizons, the 3-month and 1-year returns were -6.71% and -17.19%, respectively. This consistent underperformance highlights significant downside risk, as the stock’s price continues to fall post-earnings, suggesting no immediate market confidence in the company’s recovery.

CEO Commentary

No direct commentary from the CEO or senior leadership was provided in the earnings report or accompanying SEC filings. The 10-Q report, however, explicitly states management’s concerns about the company’s ability to continue as a going concern due to sustained net losses and operational cash flow challenges.

Guidance

No forward-looking guidance was disclosed in the Q3 2025 earnings report or associated SEC filings.

Additional News

Wellgistics Health, Inc. released its Q3 2025 Form 10-Q on November 20, 2025, detailing severe financial and operational challenges. The report highlights a 46.9% year-over-year revenue decline and a net loss of $34.32 million, driven by reduced sales volume and elevated operating expenses. Management emphasized the company’s domestic revenue focus (100% U.S.-based operations) and reiterated concerns about its ability to continue as a going concern. No non-earnings-related news, such as M&A activity, executive changes, or dividend announcements, was disclosed within the three-week period following the earnings release.